CanBas Co Ltd (4575):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CanBas Co Ltd (4575) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12323
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CanBas Co Ltd (CanBas) is a clinical stage biopharmaceutical company that develops therapeutics for cancer. The company discovers and develops of novel therapeutics in the field of oncology targeting the cell cycle. It provides two clinical oncology programs, CBP501 and CBS9106 with mutually unique MoAs. CanBas product carries out development in CBP501; a modified synthetic peptide enhances the efficacy of cisplatin without adding toxicity. CanBas’ CBP501 is in US Phase II development for first-line treatment of late stage malignant pleural mesothelioma and non-small cell lung cancer. The company’s other drug candidates, CBS9106, an orally-active synthetic small molecule of molecular mass 420, is in preclinical stage, and CBS2400 program is currently in the lead optimization stage of development. It also develops techniques to determine the drug specific sensitivity of individual cancer from a patient. CanBas is headquartered in Numazu, Japan.

CanBas Co Ltd (4575) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CanBas Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
CanBas Enters into Research Agreement with Fujifilm 10
CanBas Enters into Research Agreement with University of Shizuoka 11
Licensing Agreements 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 13
CanBas Co Ltd – Key Competitors 14
CanBas Co Ltd – Key Employees 15
CanBas Co Ltd – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Clinical Trials 17
Sep 11, 2017: Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017 17
Aug 30, 2017: Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress 18
Feb 21, 2017: Stemline Therapeutics Provides Update on SL-801 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
CanBas Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CanBas Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CanBas Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
CanBas Enters into Research Agreement with Fujifilm 10
CanBas Enters into Research Agreement with University of Shizuoka 11
Stemline Therapeutics Enters into Licensing Agreement with CanBas 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 13
CanBas Co Ltd, Key Competitors 14
CanBas Co Ltd, Key Employees 15

List of Figures
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[CanBas Co Ltd (4575):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dr. Paul Lohmann GmbH & Co KGaA:企業の戦略・SWOT・財務分析
    Dr. Paul Lohmann GmbH & Co KGaA - Strategy, SWOT and Corporate Finance Report Summary Dr. Paul Lohmann GmbH & Co KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Jiangsu Hengrui Medicine Co Ltd (600276):企業の財務・戦略的SWOT分析
    Jiangsu Hengrui Medicine Co Ltd (600276) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Wolfgang Puck Worldwide, Inc.:企業の戦略・SWOT・財務情報
    Wolfgang Puck Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report Summary Wolfgang Puck Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • INRange Systems Inc:医療機器:M&Aディール及び事業提携情報
    Summary INRange Systems Inc (INRange) is a medical device company that develops and markets medication delivery systems. The company offers EMMA, a remote medication management system that provides individual unit dose control of medication dispensing, which is managed through a web-based scheduling …
  • State Bank Of India:企業の戦略・SWOT・財務分析
    State Bank Of India - Strategy, SWOT and Corporate Finance Report Summary State Bank Of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • BNY Mellon Wealth Management:企業の戦略・SWOT・財務情報
    BNY Mellon Wealth Management - Strategy, SWOT and Corporate Finance Report Summary BNY Mellon Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Breas Medical AB:医療機器:M&Aディール及び事業提携情報
    Summary Breas Medical AB (Breas), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, is a medical device company that manufactures and markets medical devices for anesthesia and respiratory markets. The company provides isleep and vivo products. It provides products such as isleep, vivo 3 …
  • The Nisshin OilliO Group Ltd (2602):企業の財務・戦略的SWOT分析
    The Nisshin OilliO Group Ltd (2602) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Power Financial Corporation:企業の戦略・SWOT・財務情報
    Power Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary Power Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • AdvantEdge Healthcare Solutions Inc:医療機器:M&Aディール及び事業提携情報
    Summary AdvantEdge Healthcare Solutions Inc (AdvantEdge) is a healthcare service provider that offers medical billing, coding and revenue cycle management solutions. The center’s solutions include medical billing, coding, reporting, dashboards and business intelligence, consulting and practice manag …
  • Nuclear Decommissioning Authority:企業の戦略的SWOT分析
    Nuclear Decommissioning Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Rizzani de Eccher S.p.A.:企業の戦略・SWOT・財務情報
    Rizzani de Eccher S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Rizzani de Eccher S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AnaMar AB-医療機器分野:企業M&A・提携分析
    Summary AnaMar AB (AnaMar), a subsidiary of Koncentra Holding AB, discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. The company develops drug candidates from several chemical classes that concentrates on the receptors and shows poten …
  • Collegium Pharmaceutical Inc (COLL):製薬・医療:M&Aディール及び事業提携情報
    Summary Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended …
  • Response Biomedical Corp:企業の戦略的SWOT分析
    Response Biomedical Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Pendopharm-製薬・医療分野:企業M&A・提携分析
    Summary PendoPharm is a healthcare company that offers production and commercialization of a wide range of drugs. The company’s products comprise spans prescription drugs, over-the-counter and behind-the-counter products. Its prescription products offers drugs for therapeutic areas of gastroenterolo …
  • Sing Investments & Finance Ltd (S35):企業の財務・戦略的SWOT分析
    Sing Investments & Finance Ltd (S35) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • S Group:企業の戦略的SWOT分析
    S Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • TC BioPharm Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary TC BioPharm Ltd (TC BioPharm) is an immunotherapy company that develops cell based products for treatment of cancer and viral infection. The company pipeline products are intended for the treatment of ovarian cancer, breast cancer and epidermolysisbullosa related disease, among others. It wo …
  • C-squared PHARMA Sarl:製薬・医療:M&Aディール及び事業提携情報
    Summary C-squared PHARMA Sarl (C-squared PHARMA), formerly Centroflora CMS Sarl, is a pharmaceutical company that focuses on the manufacturing and commercialization of active pharmaceutical ingredients (APl) and complex chemical compounds from phytochemical and chemical origins. The company’s produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆